Form 4: Amy Schulman Trades Alnylam Pharmaceuticals Stock

Director Amy W. Schulman of Alnylam Pharmaceuticals, Inc. reported a transaction involving the exercise of stock options and the subsequent sale of common stock.

Summary

• Director Amy W. Schulman of Alnylam Pharmaceuticals, Inc. (ALNY) engaged in a transaction on May 13, 2026.
• Schulman exercised stock options to acquire 11,250 shares of common stock at an exercise price of $70.20 per share.
• Following the exercise, Schulman disposed of these 11,250 shares of common stock at a price of $70.20 per share.
• The transaction resulted in Schulman holding 23,211 shares of common stock directly after the reported transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction represents the exercise and sale of stock options, a typical compensation-related activity, rather than a strong indicator of positive or negative sentiment about the company's future prospects.

Positives

• Director Amy W. Schulman exercised stock options, indicating a potential belief in the company's value at the exercise price.
• The exercise and disposal occurred at the same price ($70.20), suggesting no immediate loss on the transaction for the shares involved.

Negatives

• Director Amy W. Schulman disposed of 11,250 shares of common stock, which could be interpreted as a reduction in direct ownership.

Future Outlook

The stock options exercised were set to expire on June 3, 2026. The transaction reported on May 13, 2026, was executed before this expiration date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. This particular filing indicates a director exercising options and selling shares at the same price, which is a common practice to monetize equity compensation before options expire.

Stakeholder Impact

• Shareholders: The disposal of shares by a director may be perceived by some shareholders as a reduction in insider commitment, though it is a standard option exercise and sale.
• Employees: This transaction is related to executive compensation and does not directly impact most employees.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Alnylam Pharmaceuticals, Amy W. Schulman, Common Stock, Beneficial Ownership